The Center for Biosimilars recaps the the top 5 articles for the week of December 18, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 18.
Number 5: A newly published study shows that adalimumab is effective in treating stricturing Crohn disease.
Number 4: Mylan announced that the US Patent Trial and Appeal Board has instituted inter partes review proceedings on all claims against 2 patents covering Sanofi’s Lantus.
Number 3: Tax disclosures show that industry group PhRMA spent millions on lobbyists, politicians, and patient groups in 2016.
Number 2: Attorney Kevin Nelson, partner at Schiff Hardin, explained the impact that the federal circuit’s ruling in Amgen v Sandoz will have on biosimilar developers.
Number 1: The FDA has accepted for review Samsung Bioepis’ Biologics License Application for SB3, a proposed trastuzumab biosimilar.
Finally, last week, our e-newsletter asked whether you think that the FDA has become more lenient in approving drugs under current leadership. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.